Matinas Biopharma
MTNB1.1904.39% ( +0.050 )
Current ValuationThe current P/E ratio is -0.16, above the reasonable range, cheaper than 18.39% of the time in the past 3 years, and the industry ranks 104/605, the industry Median -1.93.
-0.159xP/E
$1.19Stock price
$-7.46Earnings per share
-0.159xP/E
Stock price$1.19Earnings per share$-7.46
Historical Valuation
P/E ratioTypical rangeMedian
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
013263952
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.